TY - JOUR
T1 - Associations between Genetic Polymorphisms of Epidermal Growth Factor Receptor (EGFR) and survival of colorectal cancer (crc) patients treated with 5-fluorouracil-based chemotherapy
AU - Lai, Ching Yu
AU - Sung, Fung Chang
AU - Hsieh, Ling Ling
AU - Tang, Reiping
AU - Chiou, Hung Yi
AU - Wu, Fang Yang
AU - Yeh, Chih Ching
PY - 2013
Y1 - 2013
N2 - Purpose. This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy. Methods. We genotyped 3 EGFR polymorphisms including R497K, G-216T, and the (CA)n repeat, among 499 histologically confirmed CRC patients who had received 5-FU-based chemotherapy after surgery between 1995 and 2001. Survival analyses of EGFR polymorphisms were performed by the log rank test and Kaplan-Meier curves. We used the Cox proportional hazard model to evaluate the association between EGFR genotypes and clinical outcomes. Stratification analysis by gender, tumor stage, and subsite were also carried out. Results. CRC patients with the EGFR (CA)n L/L genotype compared to those with the S/S?S/L genotype had a significantly better overall survival (L, C20 repeats; S,\20 repeats) (hazard ratio (HR) 0.74; 95 % confidence interval (CI) 0.57-0.95), particularly for patients who were male (HR 0.63; 95 % CI 0.44-0.90), who had stage IV disease (HR 0.70; 95 % CI 0.49-0.99), and who had rectal cancer (HR 0.62; 95 % CI 0.42-0.92). Better survival was prominent among patients with the combined genotypes of EGFR (CA)n L/L, G-216T G/G, and R497K K/K (HR 0.51; 95 % CI 0.30-0.87), compared to those with the most common genotypes of the EGFR (CA)n S allele, G-216T G/G, and R497K R allele. Conclusions. EGFR polymorphisms can serve as prognostic predictors for CRC patients receiving 5-FU-based chemotherapy.
AB - Purpose. This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy. Methods. We genotyped 3 EGFR polymorphisms including R497K, G-216T, and the (CA)n repeat, among 499 histologically confirmed CRC patients who had received 5-FU-based chemotherapy after surgery between 1995 and 2001. Survival analyses of EGFR polymorphisms were performed by the log rank test and Kaplan-Meier curves. We used the Cox proportional hazard model to evaluate the association between EGFR genotypes and clinical outcomes. Stratification analysis by gender, tumor stage, and subsite were also carried out. Results. CRC patients with the EGFR (CA)n L/L genotype compared to those with the S/S?S/L genotype had a significantly better overall survival (L, C20 repeats; S,\20 repeats) (hazard ratio (HR) 0.74; 95 % confidence interval (CI) 0.57-0.95), particularly for patients who were male (HR 0.63; 95 % CI 0.44-0.90), who had stage IV disease (HR 0.70; 95 % CI 0.49-0.99), and who had rectal cancer (HR 0.62; 95 % CI 0.42-0.92). Better survival was prominent among patients with the combined genotypes of EGFR (CA)n L/L, G-216T G/G, and R497K K/K (HR 0.51; 95 % CI 0.30-0.87), compared to those with the most common genotypes of the EGFR (CA)n S allele, G-216T G/G, and R497K R allele. Conclusions. EGFR polymorphisms can serve as prognostic predictors for CRC patients receiving 5-FU-based chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84892782781&partnerID=8YFLogxK
U2 - 10.1245/s10434-013-3069-4
DO - 10.1245/s10434-013-3069-4
M3 - 文章
C2 - 23800895
AN - SCOPUS:84892782781
SN - 1068-9265
VL - 20
SP - S599-S606
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 3 SUPPL.
ER -